INVEGA TRINZA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for INVEGA TRINZA (INVEGA TRINZA).
Paliperidone is the major active metabolite of risperidone. It is a benzisoxazole derivative antipsychotic that antagonizes central dopamine type 2 (D2) and serotonin type 2 (5-HT2A) receptors. It also antagonizes alpha-1 and alpha-2 adrenergic, and histamine H1 receptors.
| Metabolism | Paliperidone is predominantly metabolized by dealkylation, hydroxylation, and dehydrogenation, with minor contribution from CYP2D6 and CYP3A4. It is also a substrate of P-glycoprotein (P-gp). |
| Excretion | Renal: 59-80% as unchanged drug and metabolites; fecal: 6-15%; biliary: minimal. |
| Half-life | Terminal elimination half-life: 3 to 6 months (mean 118 days) due to slow dissolution from intramuscular depot; clinical context: steady state reached after 3 injections every 3 months. |
| Protein binding | 74-84% bound to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Vd: 2-4 L/kg (extensive tissue distribution); clinical meaning: high Vd indicates extensive peripheral binding, supporting long duration. |
| Bioavailability | Intramuscular: 100% (absolute bioavailability after injection). |
| Onset of Action | Intramuscular: 3-4 months (therapeutic effect); due to long-acting formulation, initial loading with oral or shorter-acting injectable required. |
| Duration of Action | Intramuscular: 3 months (dosing interval); clinical note: maintains therapeutic levels for 3 months with minimal fluctuations. |
Administered intramuscularly (gluteal or deltoid) at 3-month intervals. Starting dose: 350 mg, 525 mg, or 700 mg based on prior stabilization dose of oral paliperidone or INVEGA SUSTENNA. Maximum dose: 700 mg.
| Dosage form | SUSPENSION, EXTENDED RELEASE |
| Renal impairment | Contraindicated in eGFR <15 mL/min/1.73m². For eGFR 15-29 mL/min/1.73m²: 350 mg initially, then 350 mg every 3 months. For eGFR 30-49 mL/min/1.73m²: 350 mg initially, then 350 mg every 3 months. For eGFR ≥50 mL/min/1.73m²: no adjustment. |
| Liver impairment | No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh Class A and B). Not studied in severe impairment (Child-Pugh Class C). |
| Pediatric use | Not approved for use in pediatric patients. Safety and efficacy not established in patients <18 years. |
| Geriatric use | No specific dose adjustment recommended, but elderly patients may have reduced renal function; assess renal function (eGFR) and adjust accordingly. Use lowest effective dose and monitor for orthostatic hypotension, sedation, and extrapyramidal symptoms. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for INVEGA TRINZA (INVEGA TRINZA).
| Breastfeeding | Paliperidone is excreted in human breast milk; M/P ratio not established. The relative infant dose is estimated at 2.8-5.1% of maternal weight-adjusted dose. Monitor infant for sedation, irritability, poor feeding, and extrapyramidal signs. Consider benefits of breastfeeding and need for maternal therapy. |
| Teratogenic Risk | INVEGA TRINZA (paliperidone palmitate) is a Pregnancy Category C drug. First trimester: Limited human data; animal studies show increased fetal resorptions and skeletal delays at high doses. Second and third trimesters: Risk for extrapyramidal and withdrawal symptoms in neonates after in utero exposure (e.g., agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress). Antipsychotic use near term may increase risk for neonatal extrapyramidal symptoms. Overall, risk-benefit analysis required. |
■ FDA Black Box Warning
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. INVEGA TRINZA is not approved for use in patients with dementia-related psychosis.
| Serious Effects |
["Hypersensitivity to paliperidone, risperidone, or any component of the formulation"]
| Precautions | ["Increased mortality in elderly patients with dementia-related psychosis","Cerebrovascular adverse events (e.g., stroke, transient ischemic attack) in elderly patients with dementia-related psychosis","Neuroleptic malignant syndrome (NMS)","Tardive dyskinesia (TD)","Metabolic changes (hyperglycemia, diabetes mellitus, dyslipidemia, weight gain)","Hyperprolactinemia","Orthostatic hypotension and syncope","Leukopenia, neutropenia, and agranulocytosis","Seizures","Potential for cognitive and motor impairment","Dysphagia","Priapism","Body temperature regulation disruption","Suicide risk","Administration errors (not interchangeable with other formulations of paliperidone)"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal body weight, blood glucose, lipid profile, and prolactin levels. Assess for extrapyramidal symptoms and orthostatic hypotension. Fetal monitoring: routine prenatal care; third-trimester ultrasound for fetal growth if indicated. Neonatal monitoring after delivery: observe for extrapyramidal symptoms, sedation, withdrawal, and respiratory status for at least 48-72 hours. |
| Fertility Effects | Paliperidone may elevate serum prolactin levels, potentially causing galactorrhea, amenorrhea, and anovulation, thereby impairing fertility. The effect is dose-dependent and reversible upon discontinuation. In males, hyperprolactinemia may reduce libido and spermatogenesis. No formal fertility studies in humans; animal studies show no direct impairment. |